Albert Einstein Cancer Center awarded NIH grant

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE ALBERT EINSTEIN CANCER CENTER and the Montefiore Einstein Center for Cancer Care received a Ruth L. Kirschstein NRSA Institutional Research Training Grant from NIH, which will provide $1.18 million in funding over five years.

This new competitive program is designed so that surgical residents in training spend two additional years in hands-on training as research fellows focused on the study of malignant tumors, the role of the immune system in tumor growth inhibition and the identification of emerging novel targets.

The 15 faculty members guiding this training, both as educators and mentors, represent six clinical and four basic science departments. Participating research fellows are expected to submit at least two abstracts to national meetings and at least one original manuscript for peer review by the completion of their training.

Table of Contents

YOU MAY BE INTERESTED IN

Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
FDA has granted an accelerated approval to RP1 (vusolimogene oderparepvec) following the agency’s Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login